Breaking News Instant updates and real-time market news.

GOL

Gol Linhas

$9.67 /

+0.53 (+5.80%)

18:42
05/07/21
05/07
18:42
05/07/21
18:42

Gol Linhas reports preliminary April traffic up 289.2%

Reports preliminary April: Capacity up 273.5%; departures up 289.6%; load factor up 3.3 p.p.

GOL Gol Linhas
$9.67 /

+0.53 (+5.80%)

05/05/21 HSBC
Gol Linhas downgraded to Hold from Buy at HSBC
04/11/21 Goldman Sachs
Gol Linhas price target lowered to $9.85 from $11.05 at Goldman Sachs
04/01/21 Itau BBA
Gol Linhas initiated with a Market Perform at Itau BBA
03/23/21 Morgan Stanley
Gol Linhas downgraded to Underweight from Equal Weight at Morgan Stanley

TODAY'S FREE FLY STORIES

Syndicate
Graphite Bio 14M share IPO priced at $17.00 » 21:15
06/24/21
06/24
21:15
06/24/21
21:15
GRPH

Graphite Bio

/

+

The deal size was…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
  • 25
    Jun
Syndicate
Elevation Oncology 6.25M share IPO priced at $16.00 » 21:13
06/24/21
06/24
21:13
06/24/21
21:13
ELEV

Elevation Oncology

/

+

The deal priced at…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
  • 25
    Jun
ELEV Elevation Oncology
/

+

Downgrade
Blackline Safety downgraded to Hold from Buy at Canaccord » 21:12
06/24/21
06/24
21:12
06/24/21
21:12
BLKLF

Blackline Safety

$7.38 /

+0.0266 (+0.36%)

Canaccord analyst Doug…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
BLKLF Blackline Safety
$7.38 /

+0.0266 (+0.36%)

04/14/21 B. Riley
Blackline Safety initiated with Buy, C$12 target at B. Riley
04/14/21 B. Riley
Blackline Safety initiated with a Buy at B. Riley
03/31/21 National Bank
Blackline Safety initiated with an Outperform at National Bank
03/30/21 National Bank
Blackline Safety initiated with an Outperform at National Bank
Initiation
Recordati initiated with a Neutral at JPMorgan » 20:18
06/24/21
06/24
20:18
06/24/21
20:18
RCDTF

Recordati

$57.00 /

+ (+0.00%)

JPMorgan initiated…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
RCDTF Recordati
$57.00 /

+ (+0.00%)

RCDTF Recordati
$57.00 /

+ (+0.00%)

04/20/21 Deutsche Bank
Recordati initiated with a Hold at Deutsche Bank
10/30/20 Goldman Sachs
Recordati downgraded to Neutral from Buy at Goldman Sachs
08/04/20 Jefferies
Recordati downgraded to Hold from Buy at Jefferies
07/31/20 Kepler Cheuvreux
Recordati downgraded to Hold from Buy at Kepler Cheuvreux
Downgrade
Polyus downgraded to Neutral from Overweight at JPMorgan » 20:16
06/24/21
06/24
20:16
06/24/21
20:16
OPYGY

Polyus

$98.01 /

+ (+0.00%)

JPMorgan analyst Anna…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
OPYGY Polyus
$98.01 /

+ (+0.00%)

09/07/20 Goldman Sachs
Polyus removed from CEEMEA Focus List at Goldman Sachs
Initiation
Adagene initiated with a Buy at China Renaissance » 20:11
06/24/21
06/24
20:11
06/24/21
20:11
ADAG

Adagene

$13.90 /

-0.09 (-0.64%)

China Renaissance analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ADAG Adagene
$13.90 /

-0.09 (-0.64%)

ADAG Adagene
$13.90 /

-0.09 (-0.64%)

03/08/21 Jefferies
Adagene initiated with a Buy at Jefferies
03/08/21 Morgan Stanley
Adagene initiated with an Overweight at Morgan Stanley
03/06/21 Goldman Sachs
Adagene initiated with a Buy at Goldman Sachs
ADAG Adagene
$13.90 /

-0.09 (-0.64%)

  • 09
    Feb
ADAG Adagene
$13.90 /

-0.09 (-0.64%)

Hot Stocks
SPDR Gold Shares holdings fall from 1,046.45MT to 1,042.87MT » 19:17
06/24/21
06/24
19:17
06/24/21
19:17
GLD

SPDR Gold Shares

$166.02 /

-0.15 (-0.09%)

This is the 2nd…

This is the 2nd consecutive decline and a 1-week low level of holdings.

ShowHide Related Items >><<
GLD SPDR Gold Shares
$166.02 /

-0.15 (-0.09%)

GLD SPDR Gold Shares
$166.02 /

-0.15 (-0.09%)

GLD SPDR Gold Shares
$166.02 /

-0.15 (-0.09%)

Hot Stocks
Genentech's Actemra receives emergency use authorization from FDA » 19:15
06/24/21
06/24
19:15
06/24/21
19:15
RHHBY

Roche

$46.60 /

+0.47 (+1.02%)

Genentech, a member of…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
RHHBY Roche
$46.60 /

+0.47 (+1.02%)

RHHBY Roche
$46.60 /

+0.47 (+1.02%)

06/14/21 Berenberg
Roche price target raised to CHF 340 from CHF 320 at Berenberg
06/10/21 Morgan Stanley
Roche price target raised to CHF 370 from CHF 345 at Morgan Stanley
06/07/21 BofA
BofA upgrades Biogen to Neutral with $400 price target after Aduhelm approved
06/02/21 Societe Generale
Roche downgraded to Hold from Buy at Societe Generale
RHHBY Roche
$46.60 /

+0.47 (+1.02%)

RHHBY Roche
$46.60 /

+0.47 (+1.02%)

RHHBY Roche
$46.60 /

+0.47 (+1.02%)

Hot Stocks
Genentech's Actemra receives emergency use authorization from FDA » 19:15
06/24/21
06/24
19:15
06/24/21
19:15
RHHBY

Roche

$46.60 /

+0.47 (+1.02%)

Genentech, a member of…

Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration has issued an Emergency Use Authorization for intravenous Actemra for the treatment of COVID-19 in hospitalized adults and pediatric patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation. The EUA is based on results from four randomized, controlled studies that evaluated Actemra for the treatment of COVID-19 in more than 5,500 hospitalized patients. The results of these studies suggest that Actemra may improve outcomes in patients receiving corticosteroids and requiring supplemental oxygen or breathing support. "Even with the availability of vaccines and declines in deaths from COVID-19 in various parts of the world, we continue to see new hospitalizations from severe forms of the disease," said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. "We are pleased that Actemra is now authorized as an option that may help improve outcomes for adults and children hospitalized with COVID-19 in the United States."

ShowHide Related Items >><<
RHHBY Roche
$46.60 /

+0.47 (+1.02%)

RHHBY Roche
$46.60 /

+0.47 (+1.02%)

06/14/21 Berenberg
Roche price target raised to CHF 340 from CHF 320 at Berenberg
06/10/21 Morgan Stanley
Roche price target raised to CHF 370 from CHF 345 at Morgan Stanley
06/07/21 BofA
BofA upgrades Biogen to Neutral with $400 price target after Aduhelm approved
06/02/21 Societe Generale
Roche downgraded to Hold from Buy at Societe Generale
RHHBY Roche
$46.60 /

+0.47 (+1.02%)

RHHBY Roche
$46.60 /

+0.47 (+1.02%)

RHHBY Roche
$46.60 /

+0.47 (+1.02%)

Initiation
Empower initiated with a Buy at DA Davidson » 19:10
06/24/21
06/24
19:10
06/24/21
19:10
EMPW

Empower

$10.07 /

+0.02 (+0.20%)

, HLLY

Holley

/

+

DA Davidson analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
EMPW Empower
$10.07 /

+0.02 (+0.20%)

EMPW Empower
$10.07 /

+0.02 (+0.20%)

06/09/21 Telsey Advisory
Empower initiated with an Outperform at Telsey Advisory
05/26/21 Benchmark
Empower initiated with a Buy at Benchmark
HLLY Holley
/

+

EMPW Empower
$10.07 /

+0.02 (+0.20%)

Periodicals
Panasonic sold all its shares in Tesla, Nikkei Asia reports » 19:05
06/24/21
06/24
19:05
06/24/21
19:05
PCRFY

Panasonic

$11.39 /

+0.245 (+2.20%)

, TSLA

Tesla

$679.98 /

+23.64 (+3.60%)

Panasonic (PCRFY) sold…

Panasonic (PCRFY) sold its entire position in Tesla (TSLA) last fiscal year, Nikkei Asia reports. The move likely earned Panasonic billions of dollars to fund new strategic ventures, the report notes. Reference Link

ShowHide Related Items >><<
TSLA Tesla
$679.98 /

+23.64 (+3.60%)

PCRFY Panasonic
$11.39 /

+0.245 (+2.20%)

PCRFY Panasonic
$11.39 /

+0.245 (+2.20%)

09/23/20 Jefferies
Panasonic downgraded to Underperform ahead of Tesla event at Jefferies
09/22/20 Jefferies
Panasonic downgraded to Underperform from Hold at Jefferies
TSLA Tesla
$679.98 /

+23.64 (+3.60%)

06/22/21 Piper Sandler
Electric vehicles will represent 94% of new car sales by 2040, says Piper
06/14/21 Canaccord
Tesla price target lowered to $812 from $974 at Canaccord
06/11/21 Credit Suisse
Tesla's Model S Plaid reinforces brand DNA, says Credit Suisse
06/11/21 Goldman Sachs
Goldman says Tesla's Model S Plaid helps illustrate technology leadership
TSLA Tesla
$679.98 /

+23.64 (+3.60%)

TSLA Tesla
$679.98 /

+23.64 (+3.60%)

PCRFY Panasonic
$11.39 /

+0.245 (+2.20%)

TSLA Tesla
$679.98 /

+23.64 (+3.60%)

PCRFY Panasonic
$11.39 /

+0.245 (+2.20%)

TSLA Tesla
$679.98 /

+23.64 (+3.60%)

Downgrade
Logitech downgraded to Neutral from Buy at Goldman Sachs » 19:04
06/24/21
06/24
19:04
06/24/21
19:04
LOGI

Logitech

$125.68 /

+0.59 (+0.47%)

Goldman Sachs analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
LOGI Logitech
$125.68 /

+0.59 (+0.47%)

LOGI Logitech
$125.68 /

+0.59 (+0.47%)

06/11/21
Fly Intel: Top five analyst downgrades
06/10/21 Morgan Stanley
Logitech downgraded to Equal Weight from Overweight at Morgan Stanley
05/03/21 Loop Capital
Logitech price target raised to $130 from $120 at Loop Capital
03/02/21 Credit Suisse
Logitech price target raised to CHF 121 from CHF 116 at Credit Suisse
LOGI Logitech
$125.68 /

+0.59 (+0.47%)

LOGI Logitech
$125.68 /

+0.59 (+0.47%)

LOGI Logitech
$125.68 /

+0.59 (+0.47%)

Upgrade
Nokia upgraded to Buy from Neutral at Goldman Sachs » 19:03
06/24/21
06/24
19:03
06/24/21
19:03
NOK

Nokia

$5.14 /

+0.085 (+1.68%)

Goldman Sachs analyst…

Goldman Sachs analyst Alexander Duval upgraded Nokia to Buy from Neutral with a price target of EUR 5.40, up from EUR 4.10. Duval sees scope for upside to Infront consensus on his latest raised estimates. The analyst added that he upgraded the stock given the roughly 25% upside to his price target and with his positive view on the stock being based on continued wireless market demand, improving product position for 5G, and scope for share gains from Chinese vendors.

ShowHide Related Items >><<
NOK Nokia
$5.14 /

+0.085 (+1.68%)

NOK Nokia
$5.14 /

+0.085 (+1.68%)

13:12 Today UBS
Nokia price target raised to EUR 5.20 from EUR 4.40 at UBS
05:07 Today UBS
Ericsson downgraded to Sell from Neutral at UBS
06/16/21
Nokia downgraded to Hold from Buy at LBBW
06/08/21 Craig-Hallum
Marvell price target raised to $63 from $52 at Craig-Hallum
NOK Nokia
$5.14 /

+0.085 (+1.68%)

NOK Nokia
$5.14 /

+0.085 (+1.68%)

NOK Nokia
$5.14 /

+0.085 (+1.68%)

NOK Nokia
$5.14 /

+0.085 (+1.68%)

On The Fly
Fly Intel: After-Hours Movers » 18:54
06/24/21
06/24
18:54
06/24/21
18:54
NKE

Nike

$133.60 /

+0.51 (+0.38%)

, BB

BlackBerry

$12.68 /

-0.46 (-3.50%)

, TNXP

Tonix Pharmaceuticals

$1.10 /

-0.025 (-2.22%)

, MRTX

Mirati Therapeutics

$162.39 /

-0.51 (-0.31%)

, CAMP

CalAmp

$14.34 /

+0.64 (+4.67%)

, FDX

FedEx

$303.91 /

+6.61 (+2.22%)

, SNX

Synnex

$121.07 /

+1.76 (+1.48%)

, TBPH

Theravance Biopharma

$17.11 /

+0.42 (+2.52%)

, OMP

Oasis Midstream Partners

$27.95 /

-2.99 (-9.66%)

, MPX

Marine Products

$17.11 /

+0.19 (+1.12%)

, SNPX

Synaptogenix

$10.93 /

+0.22 (+2.05%)

, MYSZ

My Size

$1.29 /

+0.04 (+3.20%)

Check out this evening's…

ShowHide Related Items >><<
TNXP Tonix Pharmaceuticals
$1.10 /

-0.025 (-2.22%)

TBPH Theravance Biopharma
$17.11 /

+0.42 (+2.52%)

SNX Synnex
$121.07 /

+1.76 (+1.48%)

OMP Oasis Midstream Partners
$27.95 /

-2.99 (-9.66%)

NKE Nike
$133.60 /

+0.51 (+0.38%)

MYSZ My Size
$1.29 /

+0.04 (+3.20%)

MRTX Mirati Therapeutics
$162.39 /

-0.51 (-0.31%)

MPX Marine Products
$17.11 /

+0.19 (+1.12%)

FDX FedEx
$303.91 /

+6.61 (+2.22%)

CAMP CalAmp
$14.34 /

+0.64 (+4.67%)

BB BlackBerry
$12.68 /

-0.46 (-3.50%)

NKE Nike
$133.60 /

+0.51 (+0.38%)

06/22/21 BTIG
Nike price target lowered to $153 from $162 at BTIG
06/18/21 Credit Suisse
Credit Suisse cuts Nike target to $165 on negative China trends
06/17/21 OTR Global
Nike downgraded to Mixed from Positive at OTR Global
06/16/21 Morgan Stanley
Nike price target raised to $185 from $172 at Morgan Stanley
BB BlackBerry
$12.68 /

-0.46 (-3.50%)

06/04/21 BofA
BofA moves to No Rating on Bed Bath & Beyond amid 'meme mania'
03/31/21
Fly Intel: Top five analyst upgrades
03/31/21 Canaccord
BlackBerry upgraded to Hold from Sell at Canaccord
02/16/21
Fly Intel: Top five analyst downgrades
TNXP Tonix Pharmaceuticals
$1.10 /

-0.025 (-2.22%)

02/25/21 Alliance Global Partners
Tonix price target raised to $4 from $3 at Alliance Global Partners
12/21/20 H.C. Wainwright
H.C. Wainwright reiterates Buy on Aptinyx after competitor fails in PTSD
08/20/20 Alliance Global Partners
Tonix price target raised to $3 from $2.50 at Alliance Global Partners
MRTX Mirati Therapeutics
$162.39 /

-0.51 (-0.31%)

06/04/21 Citi
Mirati Therapeutics upgraded to Buy from Neutral at Citi
05/17/21
Fly Intel: Top five analyst downgrades
05/17/21 Oppenheimer
Mirati Therapeutics downgraded to Perform from Outperform at Oppenheimer
05/17/21 Oppenheimer
Mirati Therapeutics downgraded to Perform from Outperform at Oppenheimer
CAMP CalAmp
$14.34 /

+0.64 (+4.67%)

04/23/21 Canaccord
CalAmp price target raised to $17 from $14 at Canaccord
03/18/21 Canaccord
CalAmp price target raised to $14 from $13 at Canaccord
12/18/20 JPMorgan
CalAmp downgraded to Underweight with $11 target at JPMorgan
12/18/20 JPMorgan
CalAmp downgraded to Underweight from Neutral at JPMorgan
FDX FedEx
$303.91 /

+6.61 (+2.22%)

06/23/21 Barclays
FedEx price target raised to $375 from $360 at Barclays
06/21/21 Stifel
FedEx resumed with a Buy at Stifel
06/18/21 Credit Suisse
FedEx price target raised to $364 from $351 at Credit Suisse
06/16/21 Stephens
FedEx price target raised to $360 from $350 at Stephens
SNX Synnex
$121.07 /

+1.76 (+1.48%)

06/15/21 BofA
Synnex price target raised to $145 from $121 at BofA
05/24/21 Citi
Synnex price target raised to $155 from $120 at Citi
03/23/21 Barrington
Synnex price target raised to $130 from $102 at Barrington
03/23/21 Loop Capital
Synnex price target raised to $132 from $108 at Loop Capital
TBPH Theravance Biopharma
$17.11 /

+0.42 (+2.52%)

03/09/21 SVB Leerink
Theravance Biopharma sum-of-the-parts may be worth $78/share, says SVB Leerink
02/24/21 SVB Leerink
Theravance Biopharma price target raised to $41 from $35 at SVB Leerink
11/23/20 Evercore ISI
Theravance Biopharma resumed with an Outperform at Evercore ISI
10/14/20 Morgan Stanley
Morgan Stanley upgrades Theravance Biopharma to Overweight following pullback
OMP Oasis Midstream Partners
$27.95 /

-2.99 (-9.66%)

06/01/21 Truist
Oasis Petroleum initiated with a Buy at Truist
03/30/21 RBC Capital
Oasis Midstream Partners price target raised to $22 from $19 at RBC Capital
02/08/21 JPMorgan
Oasis Midstream Partners assumed with an Underweight at JPMorgan
11/30/20 Wells Fargo
Oasis Midstream Partners upgraded to Equal Weight from Underweight at Wells Fargo
MPX Marine Products
$17.11 /

+0.19 (+1.12%)

10/15/20 B. Riley
Marine Products price target raised to $17 from $15.50 at B. Riley Securities
07/13/20 B. Riley
Marine Products price target raised to $14.50 from $11.50 at B. Riley FBR
SNPX Synaptogenix
$10.93 /

+0.22 (+2.05%)

MYSZ My Size
$1.29 /

+0.04 (+3.20%)

09/28/20 H.C. Wainwright
My Size initiated with a Buy at H.C. Wainwright
TNXP Tonix Pharmaceuticals
$1.10 /

-0.025 (-2.22%)

TBPH Theravance Biopharma
$17.11 /

+0.42 (+2.52%)

SNX Synnex
$121.07 /

+1.76 (+1.48%)

OMP Oasis Midstream Partners
$27.95 /

-2.99 (-9.66%)

NKE Nike
$133.60 /

+0.51 (+0.38%)

MRTX Mirati Therapeutics
$162.39 /

-0.51 (-0.31%)

FDX FedEx
$303.91 /

+6.61 (+2.22%)

CAMP CalAmp
$14.34 /

+0.64 (+4.67%)

BB BlackBerry
$12.68 /

-0.46 (-3.50%)

  • 25
    Jun
  • 25
    Jun
  • 23
    Mar
  • 06
    Jan
  • 28
    Oct
NKE Nike
$133.60 /

+0.51 (+0.38%)

FDX FedEx
$303.91 /

+6.61 (+2.22%)

BB BlackBerry
$12.68 /

-0.46 (-3.50%)

TNXP Tonix Pharmaceuticals
$1.10 /

-0.025 (-2.22%)

TBPH Theravance Biopharma
$17.11 /

+0.42 (+2.52%)

NKE Nike
$133.60 /

+0.51 (+0.38%)

FDX FedEx
$303.91 /

+6.61 (+2.22%)

BB BlackBerry
$12.68 /

-0.46 (-3.50%)

SNX Synnex
$121.07 /

+1.76 (+1.48%)

NKE Nike
$133.60 /

+0.51 (+0.38%)

FDX FedEx
$303.91 /

+6.61 (+2.22%)

BB BlackBerry
$12.68 /

-0.46 (-3.50%)

Hot Stocks
Starbucks CEO: No shortage of supplies in cups or coffee » 18:45
06/24/21
06/24
18:45
06/24/21
18:45
SBUX

Starbucks

$111.98 /

+0.41 (+0.37%)

In an interview on…

In an interview on CNBC's Mad Money, Kevin Johnson said traffic has been increasing as vaccinations have increased. Customers are back in stores and demand is strong, he noted, with volume in stores "at a record." Johnson added that the company is seeing "phenomenal reception" to new drinks.

ShowHide Related Items >><<
SBUX Starbucks
$111.98 /

+0.41 (+0.37%)

SBUX Starbucks
$111.98 /

+0.41 (+0.37%)

06/18/21 Tigress Financial
Tigress sees Starbucks shares hitting $130 within 12 months
04/28/21 Morgan Stanley
Starbucks price target raised to $120 from $110 at Morgan Stanley
04/28/21 MKM Partners
Starbucks price target raised to $125 from $117 at MKM Partners
04/28/21 Wedbush
Starbucks price target raised to $132 from $124 at Wedbush
SBUX Starbucks
$111.98 /

+0.41 (+0.37%)

SBUX Starbucks
$111.98 /

+0.41 (+0.37%)

SBUX Starbucks
$111.98 /

+0.41 (+0.37%)

SBUX Starbucks
$111.98 /

+0.41 (+0.37%)

Recommendations
Piper Sandler sees 'asymmetric' risk reward for Sage Therapeutics investors » 18:31
06/24/21
06/24
18:31
06/24/21
18:31
SAGE

Sage Therapeutics

$57.06 /

+0.64 (+1.13%)

Piper Sandler analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SAGE Sage Therapeutics
$57.06 /

+0.64 (+1.13%)

SAGE Sage Therapeutics
$57.06 /

+0.64 (+1.13%)

06/22/21 Mizuho
Sage Therapeutics price target lowered to $60 from $77 at Mizuho
06/16/21
Fly Intel: Top five analyst downgrades
06/16/21 Truist
Sage Therapeutics price target lowered to $60 from $70 at Truist
06/16/21 Stifel
Sage Therapeutics price target lowered to $95 from $121 at Stifel
SAGE Sage Therapeutics
$57.06 /

+0.64 (+1.13%)

SAGE Sage Therapeutics
$57.06 /

+0.64 (+1.13%)

Hot Stocks
Vista Outdoor CEO: We can't fill the demand that sits in the marketplace » 18:24
06/24/21
06/24
18:24
06/24/21
18:24
VSTO

Vista Outdoor

$45.25 /

+1.28 (+2.91%)

In an interview on…

In an interview on CNBC's Mad Money, Chris Metz said Vista's Outdoor products business had a record year. The company can't produce enough products to meet demand, he noted. New product innovation, online efforts have been driving sales, he added. Acquisitions are going to be a big part of Vista's value proposition going forward, according to Metz, with an emphasis on exploring tuck-in acquisitions. "We're just in the beginning of our growth," he said.

ShowHide Related Items >><<
VSTO Vista Outdoor
$45.25 /

+1.28 (+2.91%)

VSTO Vista Outdoor
$45.25 /

+1.28 (+2.91%)

05/27/21 Lake Street
Vista Outdoor price target raised to $53 from $50 at Lake Street
05/27/21 Wedbush
Vista Outdoor price target raised to $48 from $42 at Wedbush
05/27/21 B. Riley
Vista Outdoor price target raised to $63 from $53 at B. Riley
05/27/21 Monness Crespi
Vista Outdoor price target raised to $51 from $42 at Monness Crespi
VSTO Vista Outdoor
$45.25 /

+1.28 (+2.91%)

VSTO Vista Outdoor
$45.25 /

+1.28 (+2.91%)

VSTO Vista Outdoor
$45.25 /

+1.28 (+2.91%)

Periodicals
Robinhood's listing plans slowed by SEC back-and-forth, Bloomberg says » 18:18
06/24/21
06/24
18:18
06/24/21
18:18
HOOD

Robinhood

/

+

Robinhood's plans…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
HOOD Robinhood
/

+

HOOD Robinhood
/

+

HOOD Robinhood
/

+

Hot Stocks
Matson raises dividend 30.4%, announces 3M share repurchase plan » 18:09
06/24/21
06/24
18:09
06/24/21
18:09
MATX

Matson

$63.90 /

+0.81 (+1.28%)

The Board of Directors of…

The Board of Directors of Matson declared a third quarter dividend of 30c per common share. The dividend represents a 7c, or 30.4% increase over the prior dividend and will be paid on September 2 to all shareholders of record as of the close of business on August 5. The Board also approved a share repurchase program totaling 3M shares, or approximately 7% of outstanding common shares. As of June 24, the authorization represents approximately $190M of potential repurchases.

ShowHide Related Items >><<
MATX Matson
$63.90 /

+0.81 (+1.28%)

04/29/21
Fly Intel: Top five analyst downgrades
04/29/21 Stephens
Stephens cuts Matson to Equal Weight after muted reaction to 'really good' Q1
04/29/21 Stephens
Matson downgraded to Equal Weight from Overweight at Stephens
02/24/21 Stephens
Matson price target raised to $80 from $70 at Stephens
MATX Matson
$63.90 /

+0.81 (+1.28%)

MATX Matson
$63.90 /

+0.81 (+1.28%)

Hot Stocks
Nike provides growth targets through 2025 » 17:46
06/24/21
06/24
17:46
06/24/21
17:46
NKE

Nike

$133.60 /

+0.51 (+0.38%)

Sees sustained revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
NKE Nike
$133.60 /

+0.51 (+0.38%)

NKE Nike
$133.60 /

+0.51 (+0.38%)

06/22/21 BTIG
Nike price target lowered to $153 from $162 at BTIG
06/18/21 Credit Suisse
Credit Suisse cuts Nike target to $165 on negative China trends
06/17/21 OTR Global
Nike downgraded to Mixed from Positive at OTR Global
06/16/21 Morgan Stanley
Nike price target raised to $185 from $172 at Morgan Stanley
NKE Nike
$133.60 /

+0.51 (+0.38%)

NKE Nike
$133.60 /

+0.51 (+0.38%)

NKE Nike
$133.60 /

+0.51 (+0.38%)

NKE Nike
$133.60 /

+0.51 (+0.38%)

Syndicate
DiDi 288M share IPO price range $13.00-$14.00 » 17:45
06/24/21
06/24
17:45
06/24/21
17:45
DIDI

DiDi

/

+

Goldman Sachs, Morgan…

Goldman Sachs, Morgan Stanley, JPMorgan, BofA, Barclays, China Renaissance, Citi, HSBC and UBS are acting as joint book running managers for the offering.

ShowHide Related Items >><<
DIDI DiDi
/

+

DIDI DiDi
/

+

Earnings
Nike sees FY22 revenue over $50B, consensus $48.46B » 17:44
06/24/21
06/24
17:44
06/24/21
17:44
NKE

Nike

$133.60 /

+0.51 (+0.38%)

Sees FY22 gross margin up…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
NKE Nike
$133.60 /

+0.51 (+0.38%)

NKE Nike
$133.60 /

+0.51 (+0.38%)

06/22/21 BTIG
Nike price target lowered to $153 from $162 at BTIG
06/18/21 Credit Suisse
Credit Suisse cuts Nike target to $165 on negative China trends
06/17/21 OTR Global
Nike downgraded to Mixed from Positive at OTR Global
06/16/21 Morgan Stanley
Nike price target raised to $185 from $172 at Morgan Stanley
NKE Nike
$133.60 /

+0.51 (+0.38%)

NKE Nike
$133.60 /

+0.51 (+0.38%)

NKE Nike
$133.60 /

+0.51 (+0.38%)

NKE Nike
$133.60 /

+0.51 (+0.38%)

Hot Stocks
Nike says SNKRS app grew 90% in Q4 » 17:42
06/24/21
06/24
17:42
06/24/21
17:42
NKE

Nike

$133.60 /

+0.51 (+0.38%)

Says growth was led by…

Says growth was led by digital business. Says opportunity in FY22 is significant. Says SNKRS grew 90% in Q4. Says digital revenue represents 21% of Nike brand revenue. Says in a healthy and normalized inventory position. Comments taken from Q4 earnings conference call.

ShowHide Related Items >><<
NKE Nike
$133.60 /

+0.51 (+0.38%)

NKE Nike
$133.60 /

+0.51 (+0.38%)

06/22/21 BTIG
Nike price target lowered to $153 from $162 at BTIG
06/18/21 Credit Suisse
Credit Suisse cuts Nike target to $165 on negative China trends
06/17/21 OTR Global
Nike downgraded to Mixed from Positive at OTR Global
06/16/21 Morgan Stanley
Nike price target raised to $185 from $172 at Morgan Stanley
NKE Nike
$133.60 /

+0.51 (+0.38%)

NKE Nike
$133.60 /

+0.51 (+0.38%)

NKE Nike
$133.60 /

+0.51 (+0.38%)

NKE Nike
$133.60 /

+0.51 (+0.38%)

Hot Stocks
Granite awarded $16 rehabilitation project at Anchorage International Airport » 17:40
06/24/21
06/24
17:40
06/24/21
17:40
GVA

Granite

$41.75 /

+1.92 (+4.82%)

Granite announced that it…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
GVA Granite
$41.75 /

+1.92 (+4.82%)

GVA Granite
$41.75 /

+1.92 (+4.82%)

04/15/21 DA Davidson
Granite upgraded to Buy from Neutral at DA Davidson
04/15/21 DA Davidson
Granite upgraded to Buy from Neutral at DA Davidson
03/31/21 DA Davidson
Granite price target raised to $35 from $17 at DA Davidson
06/25/20 DA Davidson
Granite Construction price target lowered to $17 from $30 at DA Davidson
GVA Granite
$41.75 /

+1.92 (+4.82%)

GVA Granite
$41.75 /

+1.92 (+4.82%)

Initiation
Applied Therapeutics assumed with a Neutral at Goldman Sachs » 17:40
06/24/21
06/24
17:40
06/24/21
17:40
APLT

Applied Therapeutics

$24.52 /

-0.98 (-3.84%)

Goldman Sachs analyst…

Goldman Sachs analyst Madhu Kumar assumed coverage of Applied Therapeutics with a Neutral rating and $18 price target. Kumar sees challenges for Applied Therapeutics' lead asset, aldose reductase inhibitor AT-007 for galactosemia, and is "cautious" on the NDA submission guided for Q3 of 2021 "based on the current patient data in adults," noting that additional data in pediatric patients from the kids trial could improve his outlook.

ShowHide Related Items >><<
APLT Applied Therapeutics
$24.52 /

-0.98 (-3.84%)

APLT Applied Therapeutics
$24.52 /

-0.98 (-3.84%)

11/17/20 Barclays
Applied Therapeutics price target lowered to $44 from $64 at Barclays
10/08/20 Truist
Applied Therapeutics initiated with a Buy at Truist
10/08/20 Truist
Applied Therapeutics initiated with a Buy at Truist
APLT Applied Therapeutics
$24.52 /

-0.98 (-3.84%)

  • 12
    Feb
APLT Applied Therapeutics
$24.52 /

-0.98 (-3.84%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.